Background Compelling evidence links obstructive sleep apnea (OSA), a prevalent sleep disorder, to heightened morbidity and mortality. Individuals with family history (FH) of OSA exhibit increased risk of developing this sleep disorder, suggesting that genetics, in addition to demographic and lifestyle factors, are likely implicated in the pathogenesis of OSA. However, it is unclear whether a positive FH of OSA predisposes to other unfavorable health outcomes. In this regard, data on its impact on vulnerability to obesity, both a precursor and a consequence of OSA, are lacking. Objective We sought to assess the association between FH of OSA and risk of obesity. Methods The study population consisted of 612 individuals (66% male, age 48.1±17.3 years) who took part in research studies performed in the Cardiovascular/Sleep Laboratory at Mayo Clinic and had complete family history data. FH of OSA and obesity were determined from questionnaires. Demographics and medical comorbidities including OSA diagnosis were obtained from self‐reports. Body mass index (BMI, kg/m 2 ) was calculated from height and weight measures and used to determine obesity status as follows: normal weight (BMI <25 kg/m 2 ), overweight (BMI 25–29.9 kg/m 2 ), and obese (BMI ≥30 kg/m 2 ). Measurements of waist circumference were obtained to determine central obesity (defined as waist circumference ≥88 cm in women and ≥102 cm in men). Results FH of OSA was reported by twelve percent of the sample (n=72). Individuals with FH of OSA were younger and more likely to be female than those without (age: 40.8±12.6 years vs 49.1±17.6 years, P<0.0001; sex: 48.6% vs 32.2%, P=0.008). Those with positive FH had higher BMI (31.5±6.8 kg/m 2 vs 29.2±7 kg/m 2 , P=0.009), were more frequently obese (59.7% vs 39.8%, P=0.007), and had higher prevalence of central obesity (67.7% vs 53.8%, P=0.036). Multivariable regression models showed the FH of OSA was associated with 3.2‐times greater risk of obesity (95% CI 1.7–5.9, P=0.0002) and with 2.3‐times greater risk of central obesity (95% CI 1.2–4.5, P=0.011) after correcting for age, sex, OSA diagnosis, and FH of obesity. Conclusion Family history of OSA is accompanied by an increased likelihood of obesity, especially central obesity, even if subjects with FH of OSA are much younger. This relationship is independent of conventional risk factors, including OSA diagnosis, suggesting that comorbid OSA in the offspring is unlikely to be implicated. Research addressing the potential pathophysiological mechanisms underlying our findings is warranted. Support or Funding Information Research support: VKS and PS are supported by NIH HL65176. NC is supported by American Heart Association grant 16SDG27250156, and Mayo Clinic CCaTS grant Marie Ingalls Cardiovascular Research Career Development Fund. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Metabo and Mechanoreceptor Expression in Heart Failure Patients: Relationships with Neural and Cardiovascular Responses to Exercise
INTRODUCTION Heart failure (HF) is characterized by reduced exercise capacity resulting from central and peripheral mechanisms. A primary peripheral mechanism is augmented neural feedback (via group III/IV afferents) arising from the locomotor muscles. This enhanced locomotor neural feedback may result from a variety of mechanisms including increased 1) metabo and/or mechanoreceptor expression, 2) metabolite production, and/or 3) mechano/metaboreceptor sensitivity. Previous studies have shown elevated expression of purinergic 2X3 (P2X3) and cyclooxygenase (COX‐2) in HF compared to sham animal models. However, it is unknown if metabo and/or mechanoreceptor (e.g., Piezo 1 and 2) expression are elevated in human HF. Further, it is unclear if altered receptor expression is related to the cardiovascular and ventilatory responses during exercise attributed to locomotor neural afferent feedback. The purpose of this study was to 1) determine if differences exist in the expression of skeletal muscle proteins associated with metabo/mechanoreflex activity between healthy individuals (CTL) and HF patients and 2) determine relationships between protein expression and the change in ventilatory and cardiovascular responses with locomotor muscle afferent inhibition during exercise. We hypothesized that 1) HF patients will demonstrate greater skeletal muscle protein expression associated with mechano/metaboreflex activity and 2) the increased protein expression will be associated with changes in ventilation, mean arterial pressure (MAP), and catecholamines during locomotor muscle afferent feedback inhibition in HF patients. METHODS In a randomized, placebo controlled cross‐over design, 10 CTL and 6 systolic HF (Age: 60±12 vs. 60±4 yrs, p=0.96; BMI: 26±3 vs. 31±5 kg/m 2 , p=0.01, respectively) patients completed cycling exercise at 60%VO 2 peak with lumbar intrathecal fentanyl or sham. Arterial blood pressure and catecholamines were measured via radial artery catheter during exercise. On a follow up visit, a muscle biopsy from the vastus lateralis was performed to isolate and measure COX‐2, P2X3, transient receptor potential vanilloid type 1 (TRPV1), Piezo 1, and Piezo 2 protein expression. RESULTS Protein expression of P2X3, COX‐2, and TRPV1 were greater in HF compared to CTL (all, p<0.05), with no difference between groups in Piezo 1 and 2 protein expression (p>0.05). HF compared to CTL had a greater decrease in ventilation with fentanyl compared to sham (−11±8 vs. −3±9%, p=0.04, respectively), with no difference between groups in MAP or norepinephrine (p>0.05). In HF, COX expression was negatively related to the change in ventilation (r= −0.87, p=0.02), MAP (r= −0.93, p<0.01), and norepinephrine (r= −0.85, p=0.03) with fentanyl. CONCLUSIONS These data demonstrate that metaborecptors (i.e. P2X3, COX‐2, and TRPV1) are elevated in HF compared to CTL. Furthermore, protein expression of COX‐2 was related to the cardiovascular and ventilatory changes observed with fentanyl in HF patients. These findings suggest that elevated expression of metaboreflex associated proteins contribute to the augmented locomotor muscle afferent feedback during exercise in HF. Support or Funding Information NHLBI RO1 HL126638 AHA 18POST3990251 This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Respiratory Muscle Work Constrains Locomotor Convective and Diffusive Transport in Heart Failure during Exercise
Introduction Heart failure (HF) patients demonstrate augmented ventilation for a given metabolic demand which results in increased respiratory muscle work and subsequent competition for blood flow between the respiratory and locomotor muscle beds. Unloading the respiratory muscles during submaximal exercise has been shown to increase leg oxygen uptake (VO 2 ) in HF patients due increased leg blood flow via increased cardiac output and redistribution of cardiac output from the respiratory to locomotor muscles. It has been suggested that increased leg VO 2 following respiratory muscle unloading in HF during submaximal exercise is due to augmented convective O 2 transport in HF; however, it is unclear if diffusive O 2 transport also increases with respiratory muscle unloading. We hypothesized that respiratory muscle unloading during submaximal exercise will lead to increased leg VO 2 due to combined increases in convective and diffusive O 2 transport. Methods Ten HF patients with reduced systolic function (6M/4W; 53±15 yrs; BMI: 29±6 kg/m 2 ) were recruited. Patients performed two submaximal exercise bouts (i.e. with and without respiratory muscle unloading (via mechanical ventilator) (RM unloading and control (CTL), respectively)). During exercise, leg blood flow (Q L ) was measured via thermodilution. Intrathoracic pressure was measured via esophageal balloon. Radial arterial and femoral venous blood gases were measured. Blood gases were used to calculate arterial and venous oxygen content (CaO 2 and CvO 2 , respectively). Leg VO 2 was calculated as Q L multiplied by the difference between CaO 2 ‐CvO 2 . Leg O 2 delivery was calculated as Q L multiplied by CaO 2 . Leg diffusion capacity (DO 2 ) was calculated as leg VO 2 divided by femoral venous partial pressure of O 2 . Results From CTL to RM unloading, leg VO 2 increased during submaximal exercise (0.7±0.3 vs. 1.0±0.4 L/min, p<0.01, respectively). From CTL to RM unloading, leg O 2 delivery increased during submaximal exercise (0.9±0.4 vs. 1.4±0.5 L/min, p<0.01, respectively), whereas CaO 2 ‐CvO 2 was not different (14.1±3.0 vs. 14.2±3.2 mL/dL, p=0.57, respectively). From CTL to RM unloading, leg DO 2 increased during submaximal exercise (30.4±10.8 vs. 49.7±18.6 mL/mmHg, p<0.01, respectively). There was a negative relationship between the degree of RM unloading (i.e. percent decrease in mean inspiratory esophageal pressure) and percent increase in leg DO 2 with RM unloading (r= −0.77, p<0.01). Conclusion Our results demonstrate that unloading the respiratory muscles leads to increased leg VO 2 due to convective and diffusive O 2 transport during submaximal exercise in HF patients. These findings suggest that the naturally occurring respiratory muscle work in HF compromises convective and diffusive O 2 transport and thus constrains leg VO 2 during submaximal exercise in HF. Support or Funding Information NIH HL126638 AHA 18POST3990251 This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Association between Daytime Sleepiness and Cardiometabolic Risk Factors
Background Sleep disturbances are increasingly common and associated with adverse health outcomes. Inadequate sleep may also produce daytime symptoms, such as excessive sleepiness. Growing research identifies daytime sleepiness as a risk factor for morbidity and mortality. However, it is unclear whether these associations are independent of the presence of sleep disordered breathing, a primary cause of hypersomnolence. Objective In this study, we sought to assess the relation between daytime sleepiness and established cardiometabolic risk factors, independently of obstructive sleep apnea. Methods We compiled data from 456 individuals (69% male, age 51.3±15.7 years) who participated in research studies performed in the Cardiovascular/Sleep Laboratory at Mayo Clinic and had complete sleepiness data. Height and weight were measured to calculate body mass index (BMI, kg/m 2 ). Obesity was defined as BMI ≥30 kg/m 2 . Hypertension was determined as self‐reported diagnosis or taking antihypertensive medications. Diabetes mellitus was defined as patient‐reported diabetes or usage of insulin or antidiabetic drugs. Obstructive sleep apnea (OSA) was self‐reported or determined from polysomnography. Subjective daytime sleepiness was defined as an affirmative answer to the question “Are you usually sleepy during the daytime?”. Results Daytime sleepiness was reported by 51% of the subjects (n=231). Those with daytime sleepiness were more likely to be male (74.9% vs 62.3%, P=0.005), but the average age was similar between groups (51.6±17.3 years vs 51±14.1 years, P=0.67). BMI was greater among the subjects with perceived daytime sleepiness than in those without (32.2±7 kg/m 2 vs 28.9±6.8 kg/m 2 , P<0.0001), and obesity was more frequent in the former group (62.9% vs 35.4%, P<0.0001). Prevalence of hypertension (37% vs 27.5%, P=0.03), diabetes (14% vs 6.7%, P=0.01), and OSA (18.2% vs 10.4%, P=0.035) was also higher in individuals reporting sleepiness during the day. In multivariable analysis adjusted for age, sex, and OSA, daytime sleepiness was associated with increased risk of obesity (OR=2.88, 95% CI 1.84–4.49, P<0.0001), hypertension (OR=1.73, 95% CI 1.04–2.87, P=0.034), and diabetes (OR=2.58, 95% CI 1.18–5.61, P=0.017). Conclusion Daytime sleepiness is associated with greater risk of obesity, hypertension and diabetes independently of comorbid OSA. Daytime sleepiness may be a novel target for preventative and therapeutic strategies aimed at improving cardiometabolic health. Support or Funding Information NC is supported by American Heart Association grant 16SDG27250156, and Mayo Clinic Center for Clinical and Translational Science grant Marie Ingalls Cardiovascular Research Career Development Fund. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
In‐vivo genetic inactivation of CuZn‐superoxide dismutase (SOD1) prevents vascular protective effects of erythropoietin
Previous studies demonstrated that treatment with erythropoietin (EPO) prevents endothelial dysfunction and medial thickening after wire‐induced injury of mouse carotid artery. In the present study, we tested the hypothesis that stimulatory effect of EPO on expression and activity of SOD1 is an important mechanism underlying the vascular protective effect of EPO. This hypothesis was based on observation that treatment with recombinant human EPO (1000 U/kg, s.c., biweekly for 2 weeks) significantly enhanced SOD1 protein expression by 31% in arteries of wild‐type mice (P<0.05; n=3). Analysis of the vascular effects of EPO was performed in SOD1‐deficient (SOD1 −/− ) mice. Two weeks after wire‐induced injury vascular reactivity of carotid arteries was studied in‐vitro under pressurized condition, and the arteries were histologically assessed. Endothelium‐dependent relaxations to acetylcholine were impaired in carotid arteries of SOD1 −/− mice (P<0.05 vs. control SOD1 −/− mice; n=7‐8) while endothelium‐independent relaxations to nitric oxide donor, DEA‐NONOate, were unaffected. This was associated with increased medial cross sectional area (33±2 x10 −3 mm 2 ; P<0.05 vs. controls: 28±1 x10 −3 mm 2 ; n=9‐10). Treatment with EPO did not affect endothelial dysfunction or medial thickening of injured carotid arteries in SOD1 −/− mice (n=7‐10). Furthermore, EPO did not prevent increased superoxide anion production in aortas of SOD1 −/− mice. These findings suggest that the vascular protective effects of EPO are dependent on activation of SOD1.
Circulating CD34‐positive cells stimulate phosphorylation of endothelial nitric oxide synthase in cerebral arteries
In animal models, transplantation of CD34 + cells has beneficial effect on cerebral ischemia and recovery from stroke, however, the mechanism underlying cerebrovascular effects of CD34 + cells is poorly understood. In the present study, CD34 + cells were obtained by magnetic cell sorting of rabbit peripheral blood mononuclear cells. Rabbit basilar arteries were exposed to autologous CD34 + cells (~5×10 5 cells) in vitro or in vivo . Arteries treated with endothelial growth medium‐2 (EGM‐2, vehicle) served as controls. Twenty four hours after intracisternal delivery of cells, basilar arteries were isolated and studied. In arteries treated with CD34 + cells either in vivo or in vitro , protein expression of phosphorylated Ser‐473‐Akt and phosphorylated Ser‐1177 endothelial nitric oxide synthase (eNOS) were significantly increased (n = 6, P<0.05), while expressions of eNOS, Akt, inducible NOS, cyclooxygenase‐1 (COX‐1) and COX‐2 were not affected (n = 6, P>0.05). In arteries exposed to CD34 + cells in vitro , cGMP content was significantly augmented (n = 4, P<0.01), whereas cAMP levels remained unaffected (n = 4, P>0.05). Our results suggest that in basilar artery, CD34 + cells stimulate phosphorylation of Akt and eNOS thereby increasing endothelial NO production. These findings may help to explain described therapeutic effect of transplanted CD34 + cells in cerebral circulation.
Abstract 259: Genetic Inactivation of Sirt3 Does Not Alter Endothelial Function or Vascular Compliance in Hypercholesterolemic Mice
Endothelial dysfunction and arterial stiffening major risk factors associated with progression of atherosclerosis and increased risk of acute coronary events. Recent data suggest sirtuins may play a role in protecting against a variety age-related diseases, and we recently reported that sirtuins are reduced in the aging vasculature. The roles of SIRT3 (a deacetylase that is largely restricted to the mitochondria) in the regulation of vasomotor function and arterial stiffness, however, remains poorly understood. Therefore, we hypothesized that genetic inactivation of SIRT3 in hypercholesterolemic mice will impair endothelial function and reduce vascular compliance compared to hypercholesterolemic mice with normal levels of SIRT3. We used Ldlr -/- /ApoB 100/100 (LA) mice that were either wild-type for SIRT3 (LA-SIRT3 +/+ ) or null for SIRT3 (LA-SIRT3 -/- ) and fed a western diet for 12 months. At time of sacrifice, aorta was removed for isolated organ chamber baths to measure changes in endothelium-dependent relaxation to acetylcholine (ACH), and carotid arteries were harvested to assess changes in vascular compliance using a pressurized cannulation system. Surprisingly, losses of SIRT3 did not impair relaxation to ACH in aorta compared to LA-SIRT3 +/+ mice (38.2±4.4%, 37.0±4.4%, respectively). Furthermore, reductions in SIRT3 did not impact vascular compliance or distensibility in carotid arteries from the same animals. In conclusion, in contrast to our hypothesis, inactivation of SIRT3 does not impact vasomotor function or conduit vessel compliance in advanced atherosclerosis. Importantly, this and may be explained by a “floor-effect”, and future work examining the effect of SIRT3 overexpression on vascular function and pathology will be instrumental in determining its biological role and ultimate therapeutic utility.
Abstract 470: Computational Identification of NKX2-5 Binding Sites and Downstream Gene Targets Using Transcription Factor Motif and Human Heart-specific Experimental Data
Background: While NKX2-5 plays pivotal roles in human cardiac development and disease, no ChIP-Seq studies of NKX2-5 in human cardiac tissues currently exist, resulting in an incomplete understanding of its direct gene targets. Modern computational methods which identify binding sites using transcription factor motif and tissue-specific experimental data can help to fill this knowledge gap. Objective: To use computational methods to identify likely NKX2-5 binding sites and downstream gene targets using human heart-specific experimental data. Methods: Human cardiomyocyte DNAse hypersensitivity data (2 replicates) were downloaded from the Encyclopedia of DNA Elements (ENCODE) database. The position weight matrix (PWM) representing the transcription factor motif of NKX2-5 was obtained from JASPAR. We applied the Protein Interaction Quantification (PIQ) algorithm to detect NKX2-5 binding sites using the PWM and DNAse hypersensitivity data as inputs. RNA-Seq data from 108 human heart-specific samples (atrial appendages and left ventricles) were downloaded from the Genotype-Tissue Expression (GTEx) database. Protein-coding genes significantly expressed in the heart (RPKM <= 1 based on the GTEx RNA-Seq data) that were within 100kb of the predicted binding sites were then identified. Pathway analysis of these genes was performed using Ingenuity Pathway Analysis (IPA). Results: 1283 binding sites for NKX2-5 were discovered by PIQ. Of 12698 protein-coding, heart-expressed genes, 625 were within 100kb of these binding sites. The identified genes were highly enriched in physiologic categories like “Vasculogenesis” and “Development of Cardiovascular Tissue” (p = 2.36x10-9 and 2.31x10-8 respectively). Notable genes included: cardiac transcription factors (MEF2A, TBX20); growth factors (TGFB2, BMP2); muscle and ion channel function (ACTA2, BIN1), and; calcium signaling (CALM2, CAMK2D). Conclusion: By using computational analyses of transcription factor motif and human heart-specific experimental data, we have identified candidate downstream targets of NKX2-5. Future work will include validation studies in an external cohort and analysis of associations between these candidate genes and cardiac disease.
In Vivo Stimulatory Effect of Endothelial Progenitor Cells on Vasodilator Function of Rabbit Cerebral Arteries
Evidence continues to accumulate on the importance of endothelial progenitor cells (EPCs) in neovascularization of ischemic tissues and repair of injured endothelium. The present study was designed to determine the in vivo effect of EPCs on the vasomotor function of rabbit cerebral arteries. Isolated mononuclear cells from rabbit peripheral blood were cultured in endothelial growth medium (EGM‐2) for 7 days, yielding EPCs. Rabbits were injected intracisternally with either autologous EPCs (1x10 5 to 5x10 5 cells) or vehicle (EGM‐2) as control. After 24 hours, basilar arteries were isolated, vasomotor function was studied in organ chambers, and protein expression in the basilar arteries quantified by Western blot analysis. In rabbits treated with EPCs, contractions to either potassium chloride (80 mmol/L) or histamine (10 −9 to 10 −5 mol/L) were not affected. However, endothelium‐dependent relaxations to acetylcholine (10 −9 to 10 −5 mol/L) and endothelium‐independent relaxations to a NO donor, DEA‐NONOate (10 −9 to 10 −5 mol/L) were enhanced in basilar arteries from EPC‐treated rabbits. Western blot studies demonstrated increased expressions of cyclooxygenase‐2 and prostacyclin synthase (PGI 2 synthase) only in arteries exposed to EPCs. Results of the present study suggest that in vivo administration of EPCs could augment vasodilatation of the cerebral arteries by increasing vascular production of prostacyclin. Funded by NIH HL66958.
Stimulatory Effect of Erythropoietin on Endothelial Repair After Vascular Injury
Erythropoietin (EPO) fosters tissue oxygenation by stimulating erythropoiesis. More recently, EPO is recognized as a tissue protective cytokine. In this study, we tested the hypothesis that EPO promotes recovery of injured vascular endothelium. A murine model of wire‐induced injury of common carotid artery was used to examine the therapeutic effect of EPO. Recombinant human EPO (1000 U/kg, s.c., biweekly) was administered for 2 weeks after which vascular reactivity of isolated carotid arteries was studied in vitro under pressurized condition using a video dimension analyzer. Changes in vascular structure were histologically assessed. Injured arteries exhibited impairment in endothelium‐dependent relaxations to acetylcholine and increased thickness of the medial cross sectional area (P<0.05; n=5–7). EPO normalized the vasorelaxant response of injured arteries to acetylcholine and prevented the increase in medial cross sectional area (30±1 x 10 ‐3 mm 2 ; P<0.05 vs. without EPO: 37±3 x 10 ‐3 mm 2 ; n=6). The number of circulating endothelial progenitor cells (EPCs), defined as CD34 + /Flk‐1 + cells in the peripheral blood, was significantly reduced 2 weeks after vascular injury (0.016±0.005%; P<0.05 vs. non‐injured control: 0.09±0.01%), but this was entirely restored by EPO (0.212±0.08%; P<0.05; n=5). Our results indicate that EPO accelerates recovery of the injured carotid artery endothelium, and such salutary effects of EPO may reflect augmentation in circulating EPCs induced by EPO.